证券之星消息，截至2025年11月19日收盘，美好医疗(301363)报收于20.99元，下跌1.13%，换手率 0.74%，成交量2.77万手，成交额5835.49万元。 11月19日的资金流向数据方面，主力资金净流出825.82万元，占总成交额14.15%，游资资金净流入 12.79万元，占总成交额0.22%，散户资金净流入813.03万元，占总成交额13.93%。 近5日资金流向一览见下表： | 指标 | 美好医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 119.41亿元 | 112.79亿元 | 27 124 | | 净资产 | 37.02亿元 | 38.93亿元 | 41 124 | | 净利润 | 2.08亿元 | 2.12亿元 | 27 124 | | 市盈率(动) | 43.01 | 56.7 | 49 124 | | 市净率 | 3.23 | 3.97 | 76 124 | | 毛利率 | 39.34% | 51.22% | 88 124 | | 净利率 | 17.43% | 9.57% | 42 124 | | ROE | ...

Core Viewpoint - The stock of Meihao Medical (301363) has shown a slight increase in price, with significant fluctuations in capital flow, indicating mixed investor sentiment and potential opportunities for analysis [1][2]. Group 1: Stock Performance - As of November 12, 2025, Meihao Medical's stock closed at 21.99 yuan, up by 0.92%, with a turnover rate of 1.32% and a trading volume of 49,100 hands, resulting in a transaction amount of 108 million yuan [1]. - Over the past five days, the stock has experienced varying capital flows, with a net inflow of 432.06 million yuan from main funds on November 12, representing 4.0% of the total transaction amount [2]. Group 2: Financial Metrics - Meihao Medical's total market value is 12.509 billion yuan, with a net asset value of 3.702 billion yuan and a net profit of 208 million yuan, ranking 27th in the medical device industry [3]. - The company's revenue for the first three quarters of 2025 was 1.194 billion yuan, a year-on-year increase of 3.28%, while the net profit decreased by 19.25% to 208 million yuan [3]. Group 3: Institutional Ratings - In the last 90 days, 18 institutions have rated Meihao Medical, with 16 buy ratings and 2 hold ratings, indicating a generally positive outlook among analysts [4]. - The average target price set by institutions over the past 90 days is 25.2 yuan, suggesting potential upside from the current trading price [4].

Core Viewpoint - The stock of Meihai Medical (301363) has experienced a decline, with significant net outflows from major and retail investors, while the company shows mixed financial performance in recent reports [1][2][3]. Financial Performance - As of November 6, 2025, Meihai Medical's stock closed at 22.18 yuan, down 1.38% with a trading volume of 48,700 hands and a turnover of 107 million yuan [1]. - In the third quarter of 2025, the company reported a main revenue of 4.62 billion yuan, a year-on-year increase of 2.56%, while the net profit attributable to shareholders was 93.90 million yuan, up 5.89% year-on-year [3]. - For the first three quarters of 2025, the company's main revenue was 11.94 billion yuan, a year-on-year increase of 3.28%, but the net profit decreased by 19.25% to 208 million yuan [3]. Market Position and Ratios - Meihai Medical's total market value is 12.618 billion yuan, with a net asset of 3.702 billion yuan and a net profit of 208 million yuan [3]. - The company has a price-to-earnings ratio (P/E) of 45.45, which is lower than the industry average of 62.24, indicating a relatively favorable valuation [3]. - The gross margin stands at 39.34%, significantly lower than the industry average of 51.22%, while the net margin is 17.43%, higher than the industry average of 9.57% [3]. Investor Sentiment - In the last 90 days, 17 institutions have rated the stock, with 15 buy ratings and 2 hold ratings, indicating a generally positive outlook [4]. - The average target price set by institutions over the past 90 days is 25.2 yuan, suggesting potential upside from the current trading price [4]. Capital Flow Analysis - On November 6, 2025, the net outflow of major funds was 20.15 million yuan, accounting for 18.75% of the total turnover, while retail investors saw a net inflow of 24.06 million yuan, representing 22.39% of the total turnover [1][2].

Core Viewpoint - The stock of Meihao Medical (301363) has experienced a decline, with a closing price of 22.89 yuan on November 4, 2025, down 2.35% from the previous day [1] Financial Performance - For the first three quarters of 2025, Meihao Medical reported a main revenue of 1.194 billion yuan, an increase of 3.28% year-on-year [3] - The net profit attributable to shareholders was 208 million yuan, a decrease of 19.25% year-on-year [3] - The third quarter of 2025 saw a single-quarter main revenue of 462 million yuan, up 2.56% year-on-year, and a net profit of 93.90 million yuan, up 5.89% year-on-year [3] Market Activity - On November 4, 2025, the net outflow of main funds was 3.6489 million yuan, accounting for 4.48% of the total transaction amount [1][2] - Over the past five days, the stock has seen fluctuating fund flows, with significant net outflows from main funds on several days [2] Industry Comparison - Meihao Medical's total market value is 13.021 billion yuan, which is higher than the industry average of 11.456 billion yuan [3] - The company's price-to-earnings ratio (P/E) is 46.91, which is lower than the industry average of 60.95, indicating a relatively favorable valuation [3] - The gross profit margin of Meihao Medical is 39.34%, significantly lower than the industry average of 51.22% [3] Analyst Ratings - In the last 90 days, 17 institutions have rated the stock, with 15 buy ratings and 2 hold ratings [4] - The average target price set by institutions over the past 90 days is 25.2 yuan [4]

Core Viewpoint - The stock of Meihao Medical (301363) has shown mixed performance with a slight increase in price, while the capital flow indicates a net outflow from major and retail investors, suggesting cautious sentiment in the market [1][2]. Financial Performance - As of the third quarter of 2025, Meihao Medical reported a total revenue of 1.194 billion yuan, a year-on-year increase of 3.28%, while the net profit attributable to shareholders was 208 million yuan, a decrease of 19.25% [3]. - The company's gross profit margin stands at 39.34%, with a net profit margin of 17.43%, indicating a relatively strong profitability compared to the industry average [3]. Market Position - Meihao Medical's total market capitalization is 13.397 billion yuan, which is above the industry average of 11.633 billion yuan, ranking 24th out of 124 companies in the medical device sector [3]. - The company's price-to-earnings ratio (P/E) is 48.26, which is lower than the industry average of 59.7, suggesting a potentially favorable valuation [3]. Capital Flow Analysis - On October 29, 2025, the stock experienced a net outflow of 9.5456 million yuan from major investors, accounting for 9.1% of the total trading volume, while retail investors saw a net inflow of 12.33% [1][2]. - Over the past five days, the stock has seen fluctuating capital flows, with significant outflows from major investors on several days, indicating volatility in investor sentiment [2]. Analyst Ratings - In the last 90 days, 17 institutions have rated Meihao Medical, with 15 buy ratings and 2 hold ratings, reflecting a generally positive outlook among analysts [4]. - The average target price set by institutions over the past 90 days is 25.2 yuan, suggesting potential upside from the current trading price [4].

Core Viewpoint - The stock of Meihao Medical (301363) has shown a decline of 1.05% on October 28, 2025, closing at 23.46 yuan, with mixed capital flow trends indicating a slight net inflow from main funds and a net outflow from retail investors [1][2]. Financial Performance - For the third quarter of 2025, Meihao Medical reported a main revenue of 1.194 billion yuan, a year-on-year increase of 3.28%, while the net profit attributable to shareholders was 208 million yuan, a decrease of 19.25% [3]. - The company's gross profit margin stands at 39.34%, with a net profit margin of 17.43%, indicating a relatively strong profitability compared to the industry average [3]. Market Position - Meihao Medical's total market capitalization is 13.346 billion yuan, ranking 25th in the medical device industry, while its net assets are 3.702 billion yuan, ranking 40th [3]. - The company has a price-to-earnings ratio (P/E) of 48.07, which is lower than the industry average of 54.16, suggesting a potentially favorable valuation [3]. Capital Flow Analysis - On October 28, 2025, the main funds had a net inflow of 2.2667 million yuan, accounting for 2.06% of the total transaction amount, while retail investors experienced a net inflow of 109,300 yuan [1][2]. - Over the past five days, the stock has seen fluctuating capital flows, with significant net outflows from retail investors on several days, indicating varying investor sentiment [2]. Institutional Ratings - In the last 90 days, 17 institutions have rated Meihao Medical, with 15 buy ratings and 2 hold ratings, suggesting a generally positive outlook among analysts [4].

证券之星消息，截至2025年8月12日收盘，美好医疗(301363)报收于20.61元，上涨1.13%，换手率 11.99%，成交量18.73万手，成交额3.89亿元。 8月12日的资金流向数据方面，主力资金净流入4124.51万元，占总成交额10.61%，游资资金净流入 649.83万元，占总成交额1.67%，散户资金净流出4774.34万元，占总成交额12.28%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： | 指标 | 美好医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 117.24亿元 | 120.28亿元 | 33 123 | | 净资产 | 35.22亿元 | 38.99亿元 | 44 123 | | 净利润 | 5187.5万元 | 7927.36万元 | 41 123 | | 市盈率(动) | 56.5 | 69.5 | 57 123 | | 市净率 | 3.37 | 3.99 | 69 123 | | 毛利率 | 39.28% | 51.34% | 87 123 | | 净利率 | 17.54% | 10.8 ...

近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-11 | 20.38 1.75% | | -1019.91万 | -2.74% | 967.77万 | 2.60% | 52.14万 | - 0.14% | | 2025-08-08 | 20.03 | 7.17% | 5599.57万 | 11.04% | 2231.77万 | 4.40% | -7831.34万 | -15.44% | | 2025-08-07 | 18.69 -0.48% | | -597.21万 | -3.98% | 304.23万 | 2.03% | 292.99万 | 1.95% | | 2025-08-06 | 18.78 -0.27% | | -58.12万 | -0.73% | -139.02万 | -1.74% | 197.14万 | 2.47% | | 2025-08-05 | 18.83 0. ...